Acute myeloid leukaemia is an aggressive blood cancer that requires swift and powerful medical action. Modern treatments aim to bring the disease under control, restore normal blood production, and help patients return to healthier lives, though the journey differs for every individual.

How Medical Teams Approach Blood Cancer Treatment

When someone receives a diagnosis of acute myeloid leukaemia, treatment planning begins almost immediately. The main goals are to eliminate cancerous cells from the blood and bone marrow, restore normal blood cell production, and ultimately help the patient achieve the longest and healthiest life possible. Because this cancer progresses quickly if left untreated, doctors often recommend starting therapy within days of diagnosis.^[3][13]

The treatment approach depends heavily on several factors unique to each patient. Age plays an important role, as does overall health and fitness level. Doctors also consider whether the patient has other medical conditions that might affect how well they tolerate intensive treatment. Importantly, the genetic and molecular characteristics of the leukaemia cells themselves guide treatment decisions. Some genetic changes make the cancer respond better to certain therapies, while others signal that more aggressive or different approaches may be needed.^[3][14]

Medical societies and expert groups around the world have developed guidelines to help doctors choose the best treatment for each situation. These recommendations are based on years of research and clinical experience. However, despite these standard approaches, scientists continue to search for better treatments through ongoing research, including clinical trials that test new drugs and treatment combinations.^[3]

Standard Treatment Pathways

The standard treatment for acute myeloid leukaemia typically unfolds in two main phases, known as induction and consolidation. Some patients may also receive a third phase called maintenance therapy. This structured approach has been refined over decades to maximize the chances of controlling the disease while managing side effects.^[8][14]

Induction Therapy: The First Line of Attack

Induction therapy represents the most intense phase of treatment. Its goal is to rapidly reduce the number of leukaemia cells in the blood and bone marrow to achieve what doctors call complete remission. In this state, blood cell counts return to normal ranges, and less than five percent of cells in the bone marrow are leukaemia cells. Signs and symptoms of the disease disappear.^[14]

For patients who are fit enough to tolerate intensive treatment, doctors typically use a combination of chemotherapy medicines. The most common combination includes a drug called cytarabine (also known as ara-C) together with an anthracycline antibiotic such as daunorubicin or idarubicin. These powerful medicines work by interfering with the ability of cancer cells to grow and multiply. Cytarabine is given through an intravenous line continuously over several days, while the anthracycline is administered as shorter infusions.^[12][13]

This intensive treatment requires hospitalization, often lasting three to four weeks or longer. Patients need constant medical supervision because the chemotherapy destroys not only cancer cells but also many healthy blood cells. This leaves the body extremely vulnerable to infections, bleeding, and severe anaemia. During this time, patients receive blood transfusions to replace red blood cells and platelets. Antibiotics are given to prevent or treat infections, as the immune system becomes severely weakened.^[12][13]

For older adults or those with other health problems who cannot withstand intensive chemotherapy, doctors recommend less intensive approaches. These may involve lower doses of chemotherapy drugs or different types of medicines that work more gently. Common options include a drug called azacitidine or low-dose cytarabine. While less toxic, these treatments may not be as effective at achieving complete remission.^[11][13]

Side effects of induction chemotherapy can be severe and include nausea, vomiting, diarrhoea, complete hair loss, mouth sores, extreme fatigue, and increased risk of serious infections. Some patients may experience heart problems, particularly with anthracycline drugs. Fertility can be affected, sometimes permanently. Most side effects gradually improve after treatment ends, though some may persist longer.^[12][13]

Consolidation Therapy: Maintaining Remission

Once induction therapy achieves complete remission, the next phase begins. Consolidation therapy aims to destroy any remaining leukaemia cells that cannot be detected by standard tests. Without this additional treatment, the disease almost always returns.^[8][14]

Consolidation treatment usually involves additional cycles of chemotherapy, often using high doses of cytarabine. These treatments are typically given in the hospital, with patients returning home between cycles. The consolidation phase generally lasts several months and requires multiple rounds of treatment.^[12][13]

For some patients, particularly those at high risk of the disease returning, doctors may recommend a stem cell transplant (also called bone marrow transplant) as part of consolidation. This intensive procedure involves destroying all remaining bone marrow with very high doses of chemotherapy or radiation, then replacing it with healthy stem cells from a donor or from the patient themselves. Stem cell transplantation remains the only treatment with true curative potential for acute myeloid leukaemia, though it carries significant risks and is not suitable for all patients.^[3][13]

Special Treatment for Acute Promyelocytic Leukaemia

One subtype of acute myeloid leukaemia, called acute promyelocytic leukaemia, receives a unique treatment approach. This form of the disease, caused by specific genetic changes involving chromosome 15, responds remarkably well to medicines beyond standard chemotherapy.^[5][8]

Patients with this subtype receive a medicine called all-trans retinoic acid, known as ATRA. This drug works differently from chemotherapy. Instead of killing cancer cells, it causes immature leukaemia cells to mature into functional blood cells. ATRA is usually given as a pill during and after induction chemotherapy, helping achieve remission more quickly.^[12][13]

Another effective medicine for acute promyelocytic leukaemia is arsenic trioxide. This treatment speeds up the death of leukaemia cells and helps transform immature cells into healthy ones. It is particularly useful if the disease returns after initial treatment. Common side effects of ATRA include headaches, nausea, bone pain, and excessive dryness of the mouth, skin, and eyes.^[12][13]

Additional Treatment Options

In certain situations, doctors may use radiotherapy, which employs high-energy beams to kill cancer cells. This approach is most commonly used when preparing for a stem cell transplant or when leukaemia cells have spread to the brain or spinal cord, though such spread is uncommon. Radiotherapy side effects typically include hair loss in the treated area, nausea, and fatigue, which usually resolve after treatment ends.^[13]

Emerging Treatments in Clinical Trials

While standard chemotherapy remains the backbone of acute myeloid leukaemia treatment, researchers are constantly developing and testing new approaches. These investigational treatments are studied in clinical trials, which are carefully designed research studies that evaluate whether new medicines work better than existing ones and whether they are safe.^[3]

Targeted Therapies Based on Genetic Changes

One of the most promising developments in acute myeloid leukaemia treatment involves drugs designed to target specific genetic mutations found in cancer cells. Different patients have different genetic changes in their leukaemia cells, and newer medicines can exploit these differences.^[3]

A drug called venetoclax has shown particular promise, especially when combined with azacitidine or low-dose cytarabine. Venetoclax works by blocking a protein called BCL-2 that helps cancer cells survive. By interfering with this survival mechanism, the drug causes leukaemia cells to die. This combination has become an important option for older adults who cannot tolerate intensive chemotherapy. Clinical trials have demonstrated that patients receiving venetoclax plus azacitidine often achieve remission and live longer than those receiving older, less intensive treatments.^[11]

Other targeted medicines focus on specific genetic mutations. For example, drugs called FLT3 inhibitors target leukaemia cells with mutations in the FLT3 gene, which is found in about one-quarter of acute myeloid leukaemia cases. These inhibitors interfere with signals that tell cancer cells to grow and divide. Medicines in this category include midostaurin, gilteritinib, and quizartinib, each studied in different phases of treatment and at various stages of clinical trials.^[3]

Similarly, IDH inhibitors target mutations in genes called IDH1 and IDH2. These mutations occur in about fifteen to twenty percent of patients. Drugs like ivosidenib (for IDH1 mutations) and enasidenib (for IDH2 mutations) work by blocking abnormal enzymes produced by mutated genes, allowing immature blood cells to develop normally. Early trial results have shown these medicines can help some patients achieve remission when other treatments have failed.^[3]

Understanding Clinical Trial Phases

New treatments progress through several testing phases before they can be widely used. Phase I trials test whether a new treatment is safe and determine the appropriate dose. These studies involve small numbers of patients and focus primarily on identifying side effects. Phase II trials examine whether the treatment actually works against the disease and continue to monitor safety. Larger groups of patients participate at this stage. Phase III trials compare the new treatment directly against current standard therapy to determine whether the new approach offers real advantages. These trials involve hundreds or sometimes thousands of patients at medical centers across multiple countries.^[3]

Immunotherapy Approaches

Scientists are also exploring ways to harness the immune system to fight acute myeloid leukaemia. Immunotherapy treatments work by helping the body’s own defenses recognize and attack cancer cells. While these approaches have transformed treatment for some other cancers, they are still being developed for acute myeloid leukaemia.^[3]

Clinical trials are testing various immunotherapy strategies, including antibodies that bind to proteins on the surface of leukaemia cells, marking them for destruction by immune cells. Other experimental approaches involve engineering a patient’s own immune cells to recognize and kill leukaemia cells, or using vaccines designed to stimulate an immune response against the cancer.^[3]

Where Trials Are Available

Clinical trials for acute myeloid leukaemia are conducted at major cancer centers and hospitals around the world, including sites in the United States, Europe, and other regions. Patients interested in participating should discuss options with their doctors, who can help determine eligibility and explain what participation would involve. Not everyone qualifies for clinical trials, as studies have specific requirements regarding age, disease characteristics, previous treatments, and overall health status.^[3]

Most Common Treatment Methods

• Intensive Induction Chemotherapy
  • Combination of cytarabine and anthracycline drugs such as daunorubicin or idarubicin
  • Given through intravenous infusion over several days in hospital
  • Aims to achieve complete remission by killing leukaemia cells in blood and bone marrow
  • Requires hospitalization for three to four weeks or longer with close medical supervision
  • Accompanied by blood transfusions and antibiotics to support the severely weakened immune system
• Consolidation Chemotherapy
  • Multiple cycles of high-dose cytarabine given after achieving remission
  • Administered in hospital with home recovery periods between cycles
  • Continues over several months to eliminate remaining cancer cells
  • Essential for preventing disease relapse
• Non-intensive Treatment for Older or Frail Patients
  • Lower-dose chemotherapy using azacitidine or low-dose cytarabine
  • Often combined with venetoclax, a targeted therapy blocking BCL-2 protein
  • Can sometimes be given on outpatient basis
  • Causes fewer severe side effects than intensive treatment
• Stem Cell Transplantation
  • Only treatment with true curative potential
  • Involves destroying existing bone marrow with high-dose chemotherapy or radiation
  • Replacement with healthy stem cells from a donor or from the patient
  • Recommended for high-risk patients during consolidation phase
  • Carries significant risks and requires lengthy recovery period
• Targeted Therapy Based on Genetic Mutations
  • FLT3 inhibitors like midostaurin, gilteritinib, and quizartinib for FLT3-mutated leukaemia
  • IDH inhibitors such as ivosidenib and enasidenib for IDH1 or IDH2 mutations
  • Venetoclax for blocking BCL-2 protein that helps cancer cells survive
  • Work by interfering with specific molecular pathways in cancer cells
• Treatment for Acute Promyelocytic Leukaemia Subtype
  • All-trans retinoic acid (ATRA) causing immature cells to mature normally
  • Arsenic trioxide speeding cancer cell death and promoting normal cell development
  • Often combined with standard chemotherapy
  • This subtype has particularly favorable outcomes with specialized treatment
• Radiotherapy
  • High-energy beams targeting cancer cells
  • Used to prepare body for stem cell transplant
  • Treats spread to brain or spinal cord when it occurs
  • Causes temporary side effects including hair loss, nausea, and fatigue